44.201.94.72
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Sarcoma

TQB2450 with anlotinib shows promise in STS

Posted on June 10, 2022

TQB2450 combined with anlotinib showed promising activity in patients with alveolar soft part sarcoma (ASPS), according to results from a phase 2 study.

In this single-arm study, 30 patients with locally advanced or metastatic soft tissue sarcoma (LA/M STS) previously unresponsive to ≥1chemotherapy regimen were administered anlotinib orally from day 1 to day 14 every 3 weeks and TQB2450 by intravenous infusion on day 1 every 3 weeks.

The objective response rate (ORR) was 36.67%, the disease control rate (DCR) was 76.67%, and the median progression-free survival (PFS) was 7.85 months. The median overall survival was not reached

Forty percent (12/30) of participants had ASPS. Amongst these patients, the ORR was 75% and the median PFS was 23.06 months.

The most common treatment-related adverse events were hypothyroidism (76.67%), hypertriglyceridemia (63.33%), hypercholesterolemia (60.00%), and elevated blood lactate dehydrogenase (53.33%).

Reference
Liu J, Gao T, Tan Z, et al. Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2022;10:13:03.583. doi: 10.1158/1078-0432.CCR-22-0871. Epub ahead of print. PMID: 35675031.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-